Answers are grounded in this paper and cite their sources.
This special themed section of Value in Health with a focus on the health economics of vaccines seems timely with potentially various coronavirus disease 2019 (COVID-19) vaccines being close to market access. Although COVID-19 vaccines will likely not immediately be subject to health economics scrutiny, in the post–COVID-19 peak era there will soon be more emphasis on health economics when broader high-risk groups will be targeted and boosters and revaccinations are to be decided on.1 Considerations now eminent in controlling COVID-19 (eg, economic impacts, specific cost-effectiveness methodologies, basic reproduction rate estimates, real-world data calibrations, discounting of long-term effects, transmission modeling) have been present for other potentially vaccine-preventable infections for decades.
No takes yet. Share an insight, caveat, or question.
Boersma et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: